Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate-Reference-Cited by-同舟云学术

Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate

Published:2019-03-19 Issue:4 Volume:13 Page:1800159
ISSN:1862-8346
Container-title:PROTEOMICS – Clinical Applications
language:en
Short-container-title:Prot. Clin. Appl.

Author:

O'Farrell Alice C.¹,Miller Ian S.¹^ORCID,Evans Rhys¹,Alamanou Marina²,Cary Maurice³,Mallya Udupi Girish²,Lafferty Adam¹,Monsefi Naser¹,Cremona Mattia⁴,Prehn Jochen H. M.¹,Verheul Henk M.⁵,Gallagher William M.²⁶,Gehrmann Mathias⁷,Byrne Annette T.¹^ORCID

Affiliation:

1. RCSI Centre for Systems MedicineDepartment of Physiology & Medical PhysicsRoyal College of Surgeons in Ireland Dublin 2 D02 HX03 Ireland

2. OncoMark Ltd.NovaUCDBellfieldUniversity College Dublin Dublin 4 D04 V2P1 Ireland

3. Pathology Experts GmBH Basel CH‐4108 Switzerland

4. Beaumont Education Resource CentreBeaumont Hospital Dublin 9 D09 YD60 Ireland

5. Department of Medical OncologyVU University Medical Centre Amsterdam 1081HV The Netherlands

6. UCD Cancer Biology and Therapeutics LaboratorySchool of Biomolecular and Biomedical ScienceConway Institute of Biomolecular and Biomedical ResearchUniversity College Dublin Dublin D04 W6F6 Ireland

7. Bayer AG Wuppertal 42117 Germany

Funder

FP7 Industry Academia Pathways and Partnerships Marie Curie Award

Horizon 2020 research and innovation programme “Colossus”

Publisher

Wiley

Subject

Clinical Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prca.201800159

Reference39 articles.

1. FDA Vol. 2014 (Ed: Pfizer) Pfizer www.FDA.gov2013.